首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4)
【24h】

Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4)

机译:通过与细胞毒性T淋巴细胞相关抗原-4(CTLA-4)共同表达增强DNA疫苗靶向G250基因的抗狭窄癌效应

获取原文
获取原文并翻译 | 示例
           

摘要

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a negative regulator of T cell activation, which competes with CD28 for B7.1/B7.2 binding with a greater affinity. Co-expression specific antigens and extracellular domain of CTLA4 represents a promising approach to increase the immunogenicity of DNA vaccines. In this study, we evaluated this interesting approach for its enhancement on G250/MN/CA IX (G250)-specific immune responses and its anti-tumor effects in renal carcinoma mice model. Consequently, we constructed a DNA vaccine containing the G250 and the CTLA-4 gene. Vaccination with the co-expression DNA not only induced much higher level of anti-CTLA4 and anti-G250 antibody, but also increased G250-specific T cell response in mice. To evaluate the anti-tumor efficacy of the plasmids, murine models with G250-expressing tumors were generated. After injection into the tumorbearing mouse model, the plasmid carrying the co-expression gene of CTLA4 and G250 showed stronger inhibition of tumor growth than the plasmid expressing CTLA4 or G250 alone. These observations emphasize the potential of the CTLA4 and G250 co-expression DNA vaccine, which could represent a promising approach for tumor immunotherapy. (C) 2017 Published by Elsevier Masson SAS.
机译:细胞毒性T淋巴细胞相关的抗原-4(CTLA-4)是T细胞活化的负调节剂,其与B7.1 / B7.2的CD28竞争更大的亲和力。 CTLA4的共表达特异性抗原和细胞外结构域代表了增加DNA疫苗的免疫原性的有希望的方法。在本研究中,我们评估了这种有趣的方法,以提高G250 / MN / CA IX(G250) - 特异性免疫应答及其在肾癌小鼠模型中的抗肿瘤作用。因此,我们构建了含有G250和CTLA-4基因的DNA疫苗。用共表达DNA疫苗接种不仅诱导了更高水平的抗CTLA4和抗G250抗体,而且还增加了小鼠的G250特异性T细胞应答。为了评估质粒的抗肿瘤效果,产生具有G250表达肿瘤的鼠模型。在注射到肿瘤性小鼠模型后,携带CTLA4和G250的共表达基因的质粒表现出比单独表达CTLA4或G250的质粒更强的肿瘤生长抑制。这些观察结果强调CTLA4和G250共表达DNA疫苗的潜力,这可能代表肿瘤免疫疗法的有希望的方法。 (c)2017年由elestvier Masson SA发布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号